Loading
Elranatamab is Pfizer's BCMA bispecific, given under the skin every week then every two weeks, for myeloma after four prior lines.
Elranatamab is a humanised IgG2a BCMAxCD3 bispecific antibody that links T cells to BCMA-expressing plasma cells, given subcutaneously with step-up doses of 12 mg and 32 mg, then 76 mg weekly and every 2 weeks after 24 weeks in responders. In MagnetisMM-3, BCMA-naive patients had ORR 61% and CR 35% with median PFS of about 17 months, leading to accelerated approval in August 2023 after at least 4 prior lines. Cytokine release syndrome was common but mild; infections affected 70% (40% grade 3 or higher), so IVIG for hypogammaglobulinaemia and infection vigilance are central to its use. MagnetisMM-5 (with daratumumab, versus Dara-Pd) and MagnetisMM-7 (post-transplant maintenance) are the confirmatory phase 3 trials. Pfizer develops it. It is an off-the-shelf injection that recruits the patient's own T cells against myeloma without the manufacturing wait of CAR-T.
1.One arm of Elranatamab binds BCMA on the cancer cell.
Given by infusion or injection in a clinic or hospital outpatient department, so it is a Part B drug: Medicare pays 80% after the Part B deductible and the patient owes 20% coinsurance, uncapped in Original Medicare unless a Medigap policy applies. Step-up dosing is often started in hospital (Part A) because of cytokine release syndrome monitoring, then continued in the outpatient setting.
Covered under the medical benefit with prior authorisation confirming diagnosis, biomarker status and line of therapy; site-of-care policies may steer infusions away from hospital outpatient departments.
20% Part B coinsurance on a high-cost infusion adds up quickly: Medigap Plan G or N, Medicare Advantage maximum out-of-pocket, Medicaid dual eligibility, or a charity fund are the usual buffers.
Sources: Medicare.gov: Chemotherapy · Medicare.gov: Prescription drugs (outpatient, Part B). Not medical or financial advice; verify with your plan.
Sources: NICE TA1023 · NHS England Cancer Drugs Fund list. Funding decisions are indication-specific and change monthly; verify with NICE and your treating team.
Compare all products across the US, EU, UK, Japan, China and Australia →
Adults with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.
Accelerated approval on a surrogate endpoint; the confirmatory requirement was still open 3.1 years later, when the FDA's table was read. source
| Region | Year | Indication |
|---|---|---|
| US | 2023 | Relapsed/refractory myeloma after ≥4 lines (accelerated) |
| Adverse event | Any grade | Grade 3+ |
|---|---|---|
| Cytokine release syndrome | 58% | 0% |
| Infections | 70% | 40% |
| Neutropenia | - | 49% |
MagnetisMM-3 cohort A. Events listed without rates were not read from a primary source; see the label. Blank cells mean the figure was not sourced, not that it is zero.
Read for the class this product belongs to (bispecific t-cell engagers) unless the answer names the product. Population figures from the cohorts named, not a prediction for one person. Blank where no source gives a recovery figure.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Elranatamab confirmed that BCMA bispecifics are a class, not a one-off, and its protocol-built dose reduction after response set a precedent for lowering the immunosuppressive burden of T-cell engagers. Patients now have two approved BCMA bispecifics and one against GPRC5D (talquetamab). Choosing between them, and sequencing them with CAR-T, remains guided by availability and toxicity profile rather than head-to-head data.
Teclistamab showed that an off-the-shelf bispecific can approach CAR-T-like response rates in late myeloma, giving patients who cannot wait for or access cell therapy a real option. It also exposed the price: prolonged T-cell engagement causes profound immunosuppression, so infection prophylaxis and immunoglobulin replacement are now routine. Less frequent dosing after response is being adopted to reduce this burden.
Query for this drug: (TITLE:"Elranatamab" OR ABSTRACT:"Elranatamab" OR TITLE:"Elrexfio" OR ABSTRACT:"Elrexfio") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Elranatamab, not a curated reading list.
Shares Caution: T-cell redirectors and infections, BCMA expression, Step-up dosing (T-cell engagers), MagnetisMM-3: elranatamab, a second BCMA bispecific, with a switch to fortnightly dosing after response.
Shares Caution: T-cell redirectors and infections, BCMA expression, BCMA, CD3.
Shares BCMA expression, BCMA, Cytokine release syndrome (CRS), Relapsed or refractory multiple myeloma.
Shares MagnetisMM-3: elranatamab, a second BCMA bispecific, with a switch to fortnightly dosing after response, Relapsed or refractory multiple myeloma, T-cell engagers (bispecific), Multiple myeloma.
Shares MajesTEC-1: teclistamab, an off-the-shelf BCMA bispecific antibody, in heavily pretreated myeloma, BCMA, CD3, T-cell engagers (bispecific).
Shares MajesTEC-1: teclistamab, an off-the-shelf BCMA bispecific antibody, in heavily pretreated myeloma, BCMA, Relapsed or refractory multiple myeloma, Multiple myeloma.
Shares MajesTEC-1: teclistamab, an off-the-shelf BCMA bispecific antibody, in heavily pretreated myeloma, Relapsed or refractory multiple myeloma, T-cell engagers (bispecific), Multiple myeloma.
Shares MagnetisMM-3: elranatamab, a second BCMA bispecific, with a switch to fortnightly dosing after response, MajesTEC-1: teclistamab, an off-the-shelf BCMA bispecific antibody, in heavily pretreated myeloma, CD3, Relapsed or refractory multiple myeloma.